A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
Bantie L, Tadesse S, Likisa J, Yu M, Noll B, Heinemann G, Lokman NA, Ricciardelli C, Oehler MK, Beck A, Pradhan R, Milne R, Albrecht H, Wang S.
Bantie L, et al. Among authors: albrecht h.
Gynecol Oncol. 2020 Dec;159(3):827-838. doi: 10.1016/j.ygyno.2020.09.012. Epub 2020 Sep 18.
Gynecol Oncol. 2020.
PMID: 32958271